Wednesday, July 8, 2026

pharma · Dermatomyositis · Diffuse Cutaneous Systemic Sclerosis · CRBP

Corbus Pharmaceuticals

Corbus Pharmaceuticals is a pharma organization headquartered in Norwood, USA. It trades on NYSE under ticker CRBP. Primary therapeutic focus areas include Dermatomyositis, Diffuse Cutaneous Systemic Sclerosis, Cystic Fi

500 River Ridge Dr, Norwood, Massachusetts 02062, US HQ
2014 Founded
57 Employees
Public company Type
CRBP · NYSE Ticker
Company details
Status
Public
HQ
500 River Ridge Dr, Norwood, Massachusetts 02062, US
Founded
2014
Employees
57
Programs
11
Drugs
3
Patents
6
Clinical program

Lenabasum 5 mg

Phase 3 · small molecule · Diffuse Cutaneous Systemic Sclerosis

Lenabasum 5 mg for Diffuse Cutaneous Systemic Sclerosis is a Phase 3 program (small_molecule) at Corbus Pharmaceuticals Holdings with 1 ClinicalTrials.gov record(s).

← All Corbus Pharmaceuticals Holdings projects Phase 3 small molecule terminated

Internal code JBT101-SSc-002

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Corbus Pharmaceuticals Holdings
Phase
Phase 3
Modality
small_molecule
Indication
Diffuse Cutaneous Systemic Sclerosis
Status
terminated
Trials
1

Clinical trials